FierceBiotech ٣١ مايو ٢٠٢٦ ASCO: Lilly exec points to ‘nutty’ 100% response rate for in vivo CAR-T as justifying Kelonia buyout
FierceBiotech ٣١ مايو ٢٠٢٦ ASCO: Revolution Medicines confident in RAS leadership as rivals square up
FierceBiotech ٣١ مايو ٢٠٢٦ ASCO: Akeso’s ivonescimab bests PD-1 inhibitor in lung cancer chemo combos, slashing death risk by 34%
Endpoints News ٣١ مايو ٢٠٢٦ #ASCO26: Summit, Akeso drug reduces death by 34% in China lung cancer study
BioPharma Dive ٣١ مايو ٢٠٢٦ ‘Unprecedented’ Revolution data point to paradigm shift in pancreatic cancer
Novartis ٣١ مايو ٢٠٢٦ Experimental Novartis radiopharma drug shows promise in early study - The Mighty 790 KFGO
Thermo Fisher ٣١ مايو ٢٠٢٦ Is Thermo Fisher (TMO) Turning AI-Enabled Orbitraps Into a Durable Edge in Life Sciences Tools? - simplywall.st
Endpoints News ٣١ مايو ٢٠٢٦ #ASCO26: Personalized cancer vaccines may help brain cancer patients live longer
Endpoints News ٣٠ مايو ٢٠٢٦ #ASCO26: Grail’s cancer blood test isn’t ready for widespread use, experts say
BioNTech ٣٠ مايو ٢٠٢٦ BioNTech and Pfizer tout bispecifics data at ASCO, and Pazdur sees silver lining at FDA - statnews.com
FierceBiotech ٣٠ مايو ٢٠٢٦ In next-gen IO race in NSCLC, BioNTech/BMS and Pfizer are divided on overall survival approach
Pfizer ٣٠ مايو ٢٠٢٦ ASCO: In next-gen IO race, BioNTech/BMS and Pfizer are divided on overall survival approach - Fierce Biotech
Illumina ٣٠ مايو ٢٠٢٦ Illumina Oncology Launches Put Product Depth Against Rapid Share Price Gains - Yahoo Finance